Prostate cancer<unk>  is used in combination with prednisone, a corticosteroid, as a treatment for mCRPC (previously called hormone-resistant or hormone-refractory prostate cancer). This is a form of prostate cancer that is not responding to first-line androgen deprivation therapy or treatment with androgen receptor antagonists.<unk>  has received Food and Drug Administration (FDA) (28 April 2011), European Medicines Agency (EMA) (23 September 2011), Medicines and Healthcare products Regulatory Agency (MHRA) (5 September 2011) and Therapeutic Goods Administration (TGA) (1 March 2012) approval for this indication. In Australia it is covered by the Pharmaceutical Benefits Scheme when being used to treat castration-resistant prostate cancer and given in combination with prednisone/prednisolone (subject to the conditions that the patient is not currently receiving chemotherapy, is either resistant or intolerant of docetaxel, has a WHO performance status of <2, and his disease has not since become progressive since treatment with PBS-subsidised<unk>  has commenced).<unk>  may be useful for prevention of the testosterone flare at the initiation of GnRH agonist therapy in men with prostate cancer. In people previously treated with docetaxel survival is increased by 3.9 months (14.8 months versus 10.9 months for placebo). In people with castration-refractory prostate cancer but who had not received chemotherapy those who received<unk>  had a progression-free survival of 16.5 months rather than 8.3 months with placebo. After a median follow-up period of 22.2 months, overall survival was better with<unk> .
Abiraterone acetate
Bisoctrizole
Osaterone acetate
Δ4-Abiraterone
Letrozole
Ingenol mebutate
Nandrolone decanoate
Nandrolone propionate